As the concentrations of highly consumed nutrients, particularly glucose, are generally lower in tumours than in normal tissues 1,2 , cancer cells must adapt their metabolism to the tumour microenvironment. A better understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit. Here we developed a continuous-flow culture apparatus (Nutrostat) for maintaining proliferating cells in low-nutrient media for long periods of time, and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low-glucose conditions. Sensitivity to low glucose varies amongst cell lines, and an RNA interference (RNAi) screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose. We found that cell lines most sensitive to low glucose are defective in the OXPHOS upregulation that is normally caused by glucose limitation as a result of either mitochondrial DNA (mtDNA) mutations in complex I genes or impaired glucose utilization. These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS 3,4 , when cancer cells are grown in low glucose or as tumour xenografts. Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function 5 . Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.
As the concentrations of highly consumed nutrients, particularly glucose, are generally lower in tumours than in normal tissues 1,2 , cancer cells must adapt their metabolism to the tumour microenvironment. A better understanding of these adaptations might reveal cancer cell liabilities that can be exploited for therapeutic benefit. Here we developed a continuous-flow culture apparatus (Nutrostat) for maintaining proliferating cells in low-nutrient media for long periods of time, and used it to undertake competitive proliferation assays on a pooled collection of barcoded cancer cell lines cultured in low-glucose conditions. Sensitivity to low glucose varies amongst cell lines, and an RNA interference (RNAi) screen pinpointed mitochondrial oxidative phosphorylation (OXPHOS) as the major pathway required for optimal proliferation in low glucose. We found that cell lines most sensitive to low glucose are defective in the OXPHOS upregulation that is normally caused by glucose limitation as a result of either mitochondrial DNA (mtDNA) mutations in complex I genes or impaired glucose utilization. These defects predict sensitivity to biguanides, antidiabetic drugs that inhibit OXPHOS 3, 4 , when cancer cells are grown in low glucose or as tumour xenografts. Notably, the biguanide sensitivity of cancer cells with mtDNA mutations was reversed by ectopic expression of yeast NDI1, a ubiquinone oxidoreductase that allows bypass of complex I function 5 . Thus, we conclude that mtDNA mutations and impaired glucose utilization are potential biomarkers for identifying tumours with increased sensitivity to OXPHOS inhibitors.
As nutrient concentrations in tumours are different to those in normal tissues, cancer cells in vivo may have metabolic dependencies that are not shared by normal cells 6 . In particular, tumour glucose concentrations are frequently 3-to 10-fold lower than in non-transformed tissues 1, 7 , probably as a result of the high rate of glucose consumption by cancer cells and the poor tumour vasculature. To study the metabolic dependencies imposed on cancer cells by a chronically low-glucose environment, we developed a continuous-flow culture system for maintaining proliferating cells in reduced but steady glucose concentrations for long periods of time. In this system, which we call a Nutrostat, media of a defined glucose concentration is fed into a suspension culture while spent media is removed at the same rate ( Fig. 1a ). By measuring cell proliferation and glucose concentrations, glucose consumption can be predicted and glucose levels in the intake media can be adjusted so that culture glucose concentrations remain within a 0.5-mM window (Fig. 1b) . Jurkat leukaemia cells seeded into 1 mM glucose media in a traditional culture vessel rapidly ceased proliferating as glucose became depleted (Extended Data Fig. 2 ). In contrast, in a Nutrostat maintained at approximately 0.75 mM glucose, Jurkat cells proliferated exponentially at a rate that was only slightly less than in approximately 10 mM glucose (doubling time of 26 versus 24 h, Fig. 1b ). Despite having a small effect on Jurkat cell proliferation, long-term culture in low glucose caused profound metabolic changes: rates of glucose consumption, lactate production and ATP levels decreased as did levels of intermediates in the upper glycolysis and pentose-phosphate pathways (Fig. 1c, d) .
To determine whether all cancer cells respond similarly to long-term low-glucose culture, we undertook a competitive proliferation assay with a pooled collection of 28 patient-derived cancer cell lines, each marked with a lentivirally transduced DNA barcode ( Fig. 2a ). All cell lines were capable of proliferating in suspension and many were derived from blood cancers but also from breast, lung, stomach and colon cancers. The relative abundance of each cell line at the initial seeding and after three weeks in culture at 0.75 or 10 mM glucose was determined by *These authors contributed equally to this work. 1 Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, Massachusetts 02142, USA. 2 deep sequencing of the barcodes, and the change in doubling time calculated for each cell line ( Fig. 2b and Supplementary Table 1 ). Interestingly, cancer cell lines exhibit diverse responses to glucose limitation, as the proliferation of many was unaffected, whereas that of a subset was strongly reduced and another, unexpectedly, increased (Fig. 2b) . The presence or absence of known oncogenic mutations did not correlate with differences in low-glucose sensitivity.
To understand the metabolic processes that mediate the response to glucose limitation, we used a cell line of modest glucose sensitivity (Jurkat) to undertake a pooled RNAi screen of 2,752 human metabolic enzymes and small molecule transporters (15,997 total short hairpin RNAs (shRNAs); 5 to 10 shRNAs per gene) in high-or low-glucose media in Nutrostats (Fig. 2c ). For control shRNAs and the great majority of gene-targeting shRNAs, the average fold change in shRNA abundance was similar in both conditions ( Fig. 2d and Supplementary Table 2 ). However, 10.5% of shRNAs were differentially depleted and, based on our hit criteria (see Methods; for alternative criteria 8 see Supplementary Table 3 ), we identified 28 and 36 genes whose suppression preferentially inhibited cell proliferation in high or low glucose, respectively ( Fig. 2e and Extended Data Fig. 3a ). Genes selectively required in 10 mM glucose fell into several pathways but were enriched for glycolytic genes (GAPDH, ALDOA, PKM, ENO1; P , 8.6 3 10 27 ). In marked contrast, genes selectively required under 0.75 mM glucose consisted almost exclusively of the nuclear-encoded components of mitochondrial OXPHOS ( Fig. 2e ). Among the scoring genes were six of the seven nuclear-encoded core complex I subunits conserved between mammals and bacteria 9 , a significant enrichment compared to non-core subunits (P , 0.0012, Extended Data Fig. 3b ). Two genes required for OXPHOS function, ACAD9 and PISD 9,10 , also scored, as did SLC2A1, the gene encoding the GLUT1 glucose transporter. Short-term individual assays validated that efficient suppression of top scoring OXPHOS genes selectively decreased proliferation under low glucose, whereas hairpins targeting non-scoring OXPHOS genes did so to a significantly lesser extent ( Fig. 2f and Extended Data Fig. 3c ). Thus, a screen of metabolic genes pinpointed OXPHOS as the key metabolic process required for optimal proliferation of cancer cells under glucose limitation.
Given these very clear results it seemed likely that fundamental differences in mitochondrial function exist between cancer cell lines that are most sensitive (U-937, MC116, NCI-H929, KMS-26) and resistant (Raji, NCI-H82, NCI-H524, SNU-16, NCI-H2171) to glucose limitation. However, we did not detect any differences in mtDNA content, mitochondrial mass, and baseline oxygen consumption rate (OCR, Extended Data Fig. 4a, b ). Therefore, we considered whether a key difference is in the mitochondrial response to glucose limitation, which reversibly induces oxygen consumption 11 (Extended Data Fig. 4c ). Indeed, when cultured in low-glucose media, the low-glucose-sensitive cell lines upregulated OCR less than the resistant ones ( Fig. 3a ). Furthermore, in response to the mitochondrial uncoupling agent FCCP (carbonyl cyanide p-trifluoromethoxyphenylhydrazone), low-glucose-sensitive cell lines induced OCR to a lesser extent than resistant lines, indicating they have reduced spare respiratory capacities (Fig. 3b ).
We considered two explanations for why low-glucose-sensitive lines do not substantially increase oxygen consumption upon glucose limitation: first, a defect in glucose utilization that limits substrates for mitochondria; or second, a defect in OXPHOS itself. Consistent with the first possibility, glucose consumption ( Fig. 3c ) and import (Extended Data Fig. 4d ) under low-glucose conditions were defective in two (NCI-H929 and KMS-26) of the low-glucose-sensitive cell lines. Analysis of publicly available gene expression data revealed that these cell lines have low expression of the GLUT3 and GLUT1 glucose transporters, which we verified by quantitative PCR (qPCR) ( Fig. 3d ), as well as lower levels of several glycolytic enzymes (Extended Data Fig. 4e ). Using gene expression data for 967 cell lines 12 we identified additional lines with this expression signature and obtained five of them (Extended Data Fig. 5 and Supplementary Table 4 ). In low-glucose media, the five lines (LP-1, L-363, MOLP-8, D341 Med, KMS-28BM) had the predicted defect in glucose consumption and proliferation, like NCI-H929 and KMS-26 cells ( Fig. 3e and Extended Data Fig. 8b) . In all cell lines tested (KMS-26, NCI-H929, L-363, LP-1, MOLP-8), GLUT3 overexpression was sufficient to rescue these phenotypes ( Fig. 3f , g, and Extended Data Fig. 4f ), without substantially affecting proliferation in high glucose (Extended Data Fig. 4g ), arguing that a glucose utilization defect can account for why the proliferation of certain cancer cells is sensitive to low glucose. Indeed, in a competitive proliferation assay, overexpression of GLUT3 provides a growth advantage to KMS-26 cells compared to vector infected controls grown under 0.75 to 2.0 mM glucose in culture and in tumour xenografts (Extended Data Fig. 6 ).
LETTER RESEARCH
To investigate whether defects in OXPHOS may be a distinct mechanism underlying low-glucose sensitivity, we focused on U-937 cells as they have low basal OCR but normal glucose utilization ( Fig. 3c and Extended Data Fig. 4a ). Indeed, in permeabilized-cell mitochondrialfunction assays, U-937 cells had a profound defect in using substrates for complexes I (pyruvate and malate) and II (succinate), but not complex IV (TMPD (tetramethylphenylenediamine) and ascorbate) ( Fig. 3h and Extended Data Fig. 4h ). Sequencing of the seven complex I subunits encoded by the mitochondrial genome (mtDNA) revealed heteroplasmic truncating mutations in ND1 and ND5 in U-937 cells ( Fig. 3i ).
We used available cancer genome resequencing data and information from the literature 12, 13 to identify additional cell lines with mtDNA mutations in complex I subunits and obtained five, including two with the same ND5 mutation as U-937 cells ( Fig. 3j and Extended Data Fig. 7 ). Like U-937, the additional lines (BxPC3, Cal-62, HCC-1438, HCC-827, NU-DHL-1) weakly boosted OCR in low-glucose media ( Fig. 3k ) and had a proliferation defect in this condition (Extended Data Fig. 8b ). To investigate whether these phenotypes are caused by complex I dysfunction, we expressed the Saccharomyces cerevisiae NDI1 gene, which catalyses electron transfer from NADH to ubiquinone without proton translocation 5, 14 . NDI1 expression significantly increased the basal OCR of the complex I defective cells (Cal-62, HCC-827, BxPC3, U-937) and partly rescued their proliferation defect in low glucose, but did not substantially affect proliferation in high glucose (Extended Data Fig. 4f , i-l). In an alternative approach, culture of Cal-62 cells for 1.5 months in the presence of a complex I inhibitor (phenformin) produced a population of cells with significantly enriched wild-type mtDNA content and a corresponding decrease in sensitivity to low glucose, changes not observed in cells expressing NDI1 (Extended Data Fig. 9 ). Taken together, these data identify defective glucose utilization and mitochondrial dysfunction as two distinct mechanisms for conferring sensitivity to glucose limitation on cancer cell lines.
RNAi-mediated suppression of OXPHOS exacerbated the modest sensitivity of Jurkat cells to low glucose ( Fig. 2 ). Thus, we wondered whether low-glucose-sensitive cells lines may be, like LKB1-deficient cells 15 , particularly sensitive to the biguanide class of pharmacological OXPHOS inhibitors 3,4 that includes metformin and the more potent biguanide Cell line Gene Mutation Protein alteration Heteroplasmy RESEARCH LETTER phenformin 3 . Indeed, in low-glucose media, cell lines with mtDNAencoded complex I mutations (U-937, BxPC3, Cal-62, HCC-1438, HCC-827, NU-DHL-1) or impaired glucose utilization (NCI-H929, KMS-26, LP-1, L-363, MOLP-8, D341 Med, KMS-28BM) were 5-to 20-fold more sensitive to phenformin compared to control cancer cell lines or an immortalized B-cell line (Fig. 4a ), and similar results were obtained with metformin or when using direct cell counting as a readout (Extended Data Fig. 8a, b, d) . The low-glucose-sensitive cell lines, particularly those with impaired glucose utilization, tended to be more sensitive to phenformin in 0.75 than 10 mM glucose, but substantial sensitivity persisted at 1.5 to 3.0 mM glucose ( Fig. 4b and Extended Data Fig. 8c, e ). Importantly, in cells with impaired glucose utilization, GLUT3 overexpression almost completely rescued the phenformin sensitivity specific to the low-glucose condition, such that GLUT3-expressing cells in 0.75 mM glucose and control cells in 10 mM glucose were similarly affected by phenformin ( Fig. 4c ). Likewise, in cells with mutations in complex I, NDI1 expression almost completely rescued the effects of phenformin on proliferation ( Fig. 4d ) and oxygen consumption ( Fig. 4e and Extended Data Fig. 8g ). Phenformin sensitivity is restricted to cells with the intermediate levels of mitochondrial dysfunction typically seen in cancer cells, as cells lacking mtDNA (143B Rho) are insensitive to phenformin but sensitive to low glucose (Extended Data Fig. 8h ). Consistent with these findings and with the low-glucose environment of tumours 1,2,7 , phenformin inhibited the growth of mouse tumour xenografts derived from cancer cells with mtDNA mutations (Cal-62, U-937) or poor glucose consumption (KMS-26, NCI-H929), but not from cells lacking these defects (NCI-H2171 and NCI-H82) ( Fig. 4f, g) . The effects of phenformin on tumour xenograft growth were rescued in mtDNA mutant cells by the introduction of NDI1, and in KMS-26 cells by the overexpression of GLUT3 ( Fig. 4g and Extended Data Fig. 8f ), demonstrating that the effect of phenformin on these xenografts has a cell-autonomous component. Thus, the glucose-utilization gene signature described earlier and mutations in mtDNA-encoded complex I subunits may serve as biomarkers for identifying tumours that are particularly sensitive to phenformin treatment. Such tumours are probably relatively common, as the prevalence of truncating mutations in mtDNA-encoded OXPHOS components is reported to be as high as 16% 16 and we detect the low-glucose-import gene expression signature in at least 5% of cell lines profiled (of which multiple myeloma and small cell lung cancer are significantly enriched). Interestingly, a number of 
retrospective studies report survival benefits for cancer patients taking metformin 17, 18 , although it has been unclear whether these effects of metformin are cancer cell-autonomous 15, 19, 20 .
In conclusion, we find that cancer cells exhibit diverse responses to glucose limitation and identify defects in glucose utilization and mitochondrial function as major determinants of low-glucose sensitivity (Extended Data Fig. 1 ). These biomarkers may pinpoint cancer cells that are likely to respond to OXPHOS inhibition alone under tumourrelevant glucose concentrations. Such a targeted strategy may be better tolerated than previously proposed approaches of combining inhibition of OXPHOS and glycolysis [21] [22] [23] . Moreover, our findings underscore the importance of considering glucose concentrations when evaluating the sensitivity of cancer cells to biguanides or other OXPHOS inhibitors. The methods described here should be valuable for studying the responses of cancer cells to tumour-relevant concentrations of other highly consumed nutrients, such as amino acids 24 , and to additional compounds that target metabolism.
METHODS SUMMARY
Glucose concentrations were maintained in Nutrostats by continuous flow of fresh media at defined glucose concentrations and simultaneous removal of spent media at a fixed rate. Competition assays were carried out at 10 or 0.75 mM glucose in Nutrostats using cell lines barcoded with lentivirally transduced seven-base-pair sequences. Nutrostats were used under similar conditions for the pooled RNAi screen of 2,752 metabolic genes and metabolite transporters. Barcode or shRNA abundances in cells were determined using deep sequencing and compared to initial cultures. Genome resequencing data were used to identify cancer cell lines with mitochondrial genome mutations and the Seahorse Extracellular Flux Analyzer was used to assay mitochondrial function. Defects in glucose import were identified using expression analyses of genes encoding glucose transporters and glycolytic enyzmes.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
The following abbreviations appear in Fig. 1d : 2-HG, 2-hydroxyglutarate; 5-HIAA, 5-hydroxyindoleacetic acid; ADP, adenosine diphosphate; AMP, adenosine monophosphate; cAMP, cyclic AMP; CDP, cytidine diphosphate; CMP, cytidine monophosphate; CE, ceramide; DAG, diacylglycerol (fatty acids additionally have annotations indicating the number of carbons and number of unsaturated linkages separated by a colon (for example, 18:2)); F1P, fructose 1-phosphate; F16DP, fructose 1,6diphosphate; F26DP, fructose 2,6-diphosphate; F6P, fructose 6-phosphate; FCCP, carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone; fruc, fluctose; G1P, glucose 1-phosphate; G16DP, glucose 1,6-diphosphate; G6P, glucose 6-phosphate; GDP, guanosine diphosphate; Gal, galactose; Glu, glucose; GMP, guanosine monophosphate; IMP, inosine monophosphate; Mal, malate; NAD 1 /NADH, nicotinaminde adenine dinucleotide (oxidized and reduced forms); NADP, nicotinaminde adenine dinucleotide phosphate; PEP, phosphoenolpyruvate; 3-PGA, 3-phosphoglycerate; Py, pyruvate; TMPD, N,N,N9,N9-tetramethyl-p-phenylenediamine; UDP, uridine diphosphate; UMP, uridine monophosphate. Cell lines and reagents. Cell lines were obtained from the Broad Institute Cancer Cell Line Encyclopedia with the exceptions of HL-60, Daudi, HuT 78, MC116, Raji and U-937, which were kindly provided by R. Weinberg, KMS-26 and KMS-27, which were purchased from the JCRB Cell Bank, Immortalized B lines 1 and 2, which were provided by C. Klein, and Cal-62, which was provided by J. A. Fagin. To normalize for media-specific effects on cell metabolism, all cell lines were grown in RPMI base medium containing 10% heat inactivated fetal bovine serum, 2 mM glutamine, penicillin and streptomycin. The NDI1 antibody is a kind gift of T. Yagi. Additional antibodies used are: Actin (I-19, Santa Cruz), Glut3 (ab15311, Abcam), RPS6 (Cell Signaling), CYC1 (Sigma) and UQCRC1 (H00007384-B01P, Novus).
Cell lines are from the following cancer origins: PANC1 (pancreas), NCI-H838 (lung), NCI-H596 (lung), NCI-H1792 (lung), A549 (lung), NU-DHL-1 (lymphoma), BxPC3 (pancreas), Cal-62 (thyroid), HCC-1438 (lung), HCC-827 (lung), L-363 (plasma cell leukaemia), MOLP-8 (multiple myeloma), LP-1 (multiple myeloma). Additional cell lines and their tissue origins are listed in Supplementary Table 1 . One cell line (SNU-1) was randomly selected for authentication by short tandem repeat (STR) profiling, and cell lines were authenticated by mtDNA sequencing (NCI-H82, Jurkat, NU-DHL-1, U-937, BxPC3, Cal-62, HCC-1438, HCC-827, Raji, MC116, KMS-26, NCI-H929, NCI-H2171).
Lentiviral shRNAs were obtained from The RNAi Consortium (TRC; http:// www.broadinstitute.org/rnai/trc/lib) collection of the Broad Institute. The TRC numbers for the shRNAs used are below. For each gene, the order of the TRC numbers matches the order of the shRNAs as numbered in the manuscript. CYC1 (TRCN0000064606, TRCN0000064603, TRCN0000064605); UQCRC1 (TRCN 0000233157, TRCN0000046484, TRCN0000046487); NDUFA7 (TRCN0000026423, TRCN0000026454); NDUFB1 (TRCN0000027148, TRCN0000027173); COX5A (TRCN0000045961, TRCN0000045960); UQCRH (TRCN0000046528, TRCN 0000046530); UQCRFS1 (TRCN0000046522, TRCN0000046519); NDUFB10 (TRCN0000026589, TRCN0000026579); UQCR11 (TRCN0000046465, TRCN 0000046467); NDUFA11 (TRCN0000221374, TRCN0000221376); NDUFV1 (TRCN0000221380, TRCN0000221378); PKM (TRCN0000037612, TRCN0000 195405); RFP (TRCN0000072203).
The retroviral SLC2A3 vector was generated by cloning into the BamHI and EcoRI sites of the pMXS-ires-blast vector a cDNA insert generated by PCR from a cDNA from Open Biosystems (catalogue number MHS1010-7429646) using the primers below, followed by standard cloning techniques: SLC2A3 (BamHI) forward, GCATGGATCCACCATGGGCACACAGAAGGTCAC; SLC2A3 (MfeI) reverse, GCATCAATTGTTAGACATTGGTGGTGGTCTCC.
The retroviral NDI1 vector was generated by cloning into the EcoRI and XhoI sites of the pMXS-ires-blast vector a cDNA insert generated by PCR from a yeast genomic library using the primers below, followed by standard cloning techniques: Ndi1 (EcoRI) forward, ATGAATTCCATCACATCATCGAATTAC; Ndi1 (XhoI) reverse, ATCTCGAGAAAAGGGCATGTTAATTTCATCTATAAT. Nutrostat design. Equipment used in constructing the Nutrostat (Fig. 1 , see also Extended Data Fig. 10 for schematic): peristaltic pumps with accompanying tubing (Masterflex, manufacturer no. 77120-42), 500 ml spinner flasks (Corning, product no. 4500-500), 9-position stirplate (Bellco Glass, manufacturer no. 7785-D9005) or LABDISC magnetic stirrer (VWR no. 97056-526), Tygon tubing (Saint Gobain Performance Plastics, manufacturer no. ACJ00004 (outlet, 3/3299 3 5/3299) and ABW00001 (inlet, 1/3299 3 3/3299), Outlet filter (Restek, catalogue no. 25008), vented caps for source and waste containers (Bio Chem Fluidics, catalogue no. 00945T-2F), and outlet tubing check valve (Ark-plas, catalogue no. AP19CV0012SL) to prevent backflow. Spinner flasks were siliconized before each use using Sigmacote (Sigma SL2) according to the manufacturer's method, and autoclaved. The outlet filter was cleaned before use by passing phosphate buffered saline and then 70% ethanol through the filter in both the forward and reverse directions. Plastic tubing was replaced before each experiment and was cut to 50-to 60-cm pieces and threaded through the caps for the source or waste vessel, over the peristaltic pump, and through the caps on the spinner flask. The outlet tubing was cut approximately 5 cm from the spinner flask to allow for the introduction of the check valve and prevent back-flow of medium. Tubing was adjusted to the following heights: source vessel, bottom; spinner flask inlet, 3 cm from cap (above media level); spinner flask outlet 1 filter, empirically adjusted so that the volume of media in the vessel is maintained at 500 ml; waste vessel, 2 cm from the cap. The entire assembled setup was autoclaved before use. The flow rate of the inlet peristaltic pump was adjusted empirically to 100 ml per day using phosphate buffered saline before the introduction of culture media, and the flow rate of the waste pump was set to safely exceed 100 ml per day to prevent accumulation of medium in the vessel. Some escape of cells from the vessel and accumulation in the waste vessel was unavoidable. Medium was sampled directly from the vessel by pipette. The mass of glucose consumed by the Nutrostat over time was modelled by the following equation:
where N 0 is the starting cell number, Q glucose is the consumption rate of glucose (g per cell per day), a is the doubling time of the cell line (days), and t is time (days). The values for N 0 , Q glucose and a were empirically determined before the start of the experiment. The Nutrostat glucose consumption was calculated in hourly increments and balanced by the amount of glucose leaving or entering the chamber such that G nutrostat over the Pooled shRNA screening. The 2,752 transporters and metabolic enzymes targeted in this study were identified as described 25 and are listed in Supplementary  Table 2 . Lentiviral plasmids encoding approximately 15,000 shRNAs targeting these genes (median of 5 shRNAs per gene) as well as 30 non-targeting control shRNAs were obtained and combined to generate a single plasmid pool, the composition of which is described in Supplementary Table 2 . Plasmid pools were used to generate lentivirus-containing supernatants and target cell lines were infected in 2 mg ml 21 polybrene as described 25 . Specifically, the titre of lentiviral supernatants was determined by infecting targets cells at several concentrations, counting the number of drug resistant infected cells after 3 days of selection. Thirty-million target cells were infected at an multiplicity of infection of approximately 0.5 to ensure that most cells contained only a single viral integrant and ensure proper library complexity. Infected cells were selected with 0.5 mg ml 21 puromycin for 3 days. Cells containing shRNA pools were used to inoculate Nutrostats at approximately 15 million cells per 500 ml culture. Glucose concentrations were measured daily and adjusted as described above. Cultures were diluted once to ensure the cell density never exceeded 500,000 cells per ml. Cultures were collected for genomic DNA extraction after approximately 15 population doublings, and samples were processed as described 25 except that two rounds of PCR were used and the primers used to amplify shRNA inserts and perform deep sequencing (Illumina) are as provided below. shRNAs present at fewer than 100 reads in the initial post-infection sample were eliminated from further analysis. Because the lentiviral pool contained shRNA expression vectors pLKO.1 and pLKO.005, to eliminate any backbone-specific amplification bias, the abundance measurements of shRNAs in the pLKO.005 vector were normalized such that the distribution of shRNA abundances in the pLKO.005 vector matched the distribution of shRNA abundances in the pLKO.1 vector in each sample. Individual shRNAs were identified as differentially scoring in high glucose versus low glucose using a log 2 fold change cutoff of 20.75 (high glucose versus low glucose). For each comparison, genes were considered hits if .33% of the shRNAs targeting that gene scored when averaging across all replicates ('Per cent shRNAs scoring' reported in Fig. 2e ). Pathways scoring as preferentially required in low glucose are complex I (P , 9.3 3 10 249 ), III (P , 6.6 3 10 220 ), IV (P , 8.3 3 10 210 ) and V (P , 5.6 3 10 219 ). The 1 or 2 genes from complex I, III and IV that scored most highly according to 'Per cent shRNAs scoring', were chosen for validation and are reported in Fig. 2f (complex I genes NDUFV1 and NDUFA11, and complex III genes CYC1 and UQCRC1) and Extended Data Fig. 3 (complex IV gene COX5A). Complex I was studied further in Fig. 3i-k and Fig. 4 using a specific inhibitor (phenformin), as this was the most significantly scoring pathway and because mutations were identified in mitochondrially encoded complex I subunits in several cell lines, and a high prevalence of somatic mutations in mtDNA-encoded complex I genes have been reported previously in human tumours.
LETTER RESEARCH
The GENE-E program 8 (Broad Institute) was used as an alternative method for identifying hits from RNAi-based screens, and these results are reported in Supplementary Table 3 . These alternative methods all identify highly significant numbers of complex I, III, IV and V genes as being differentially essential in 0.75 mM glucose. Primers for amplifying shRNAs encoded in genomic DNA: first round of PCR (15 cycles), forward, AATGGACTATCATATGCTTACCGTAACTTGAAAGTA TTTCG, reverse, CTTTAGTTTGTATGTCTGTTGCTATTATGTCTACTATTC TTTCCC; second round of PCR, barcoded forward primer (N indicates locations of sample-specific barcode sequences), AATGATACGGCGACCACCGAGAAA GTATTTCGATTTCTTGGCTTTATATATCTTGTGGANNNNACGA; common reverse primer, CAAGCAGAAGACGGCATACGAGCTCTTCCGATCTTGTG GATGAATACTGCCATTTGTCTCGAGGTC; Illumina sequencing primer, AG AAAGTATTTCGATTTCTTGGCTTTATATATCTTGTGGA. Cell barcoding. To mark individual cell lines with DNA barcodes, a unique sevenbase-pair sequence was transduced into cells using lentiviruses produced from a pLKO.1P vector into which the following sequence was cloned using the following primers, which had been annealed and ligated to a restriction-enzyme-cut vector (AgeI and EcoRI restriction enzymes): sequence inserted (N indicates locations of cell-specific barcode sequences): TTTTAGCACTGCCNNNNNNNCTCGCGGG CCGCAGGTCCAT; primers, top, CCGGTTTTTAGCATCGCCNNNNNNNCT CGCGGCCGCAGGTCCATG, bottom, AATTCATGGACCTGCGGCCGCGAG NNNNNNNGGCGATGCTAAAAA.
The sequence of individual lentiviral vectors was determined by Sanger sequencing and vectors containing unique sequences were chosen for transduction into cell lines. Each cell line was infected with three barcodes in separate infections so that the proliferation of each cell line could be measured three times independently in a single experiment. Proliferation assays of the individually barcoded cell lines verified that the barcodes did not affect cell proliferation in short term assays. To perform the cell competition assays, all of the barcoded cell lines were mixed in equal proportion with bias for overrepresentation of slower-proliferating cell lines in the initial population. The Nutrostats were inoculated with 5 million pooled cells at 10 mM or 0.75 mM glucose concentrations and the proliferation and glucose consumption of the culture carefully monitored to adjust for any timedependent changes in the per-cell glucose consumption rate. After 15 population doublings, cells were collected for genomic DNA isolation and processed for deep sequencing as described above. Barcode abundance was determined in the starting population or after 15 where 293 h is the duration of the experiment, log 2 FC cell line is the log 2 fold change in abundance of barcode for the given cell line in the final sample compared to the initial, log 2 FC Jurkat is the log 2 fold change for the Jurkat cell line, and PD Jurkat is the empirically determined number of population doublings that the Jurkat cell line underwent during 293 h (that is, 12.2 doublings in 10 mM glucose and 11.3 doublings in 0.75 mM glucose conditions). These calculated doubling times are reported for each barcode replicate in Supplementary Table 1 . Glucose consumption and uptake. Cells were plated in 10 mM or 0.75 mM glucose medium at 5,000 to 20,000 cells per ml in 24-well plates in 1 ml medium in replicates of four. Media were collected after 4 days of culture and the number of cells counted. Harvested media were assayed by a glucose oxidase assay and the absorbance at 500 nm determined of assay buffer plus spent media, media from control wells containing no cells, or media containing no glucose, allowing the concentration of glucose in the spent media to be calculated according to Beer's Law. The mass of glucose consumed was normalized to the average number of cells present in the well, which was calculated by integrating the number of cells present during the course of the experiment over 4 days assuming simple exponential growth of the cells during the course of the experiment from the measured starting to final number of cells. For glucose import, cells were incubated in 0.75 mM glucose medium overnight. The following day, Tritium-labelled 2-DG (5 mCi ml 21 , Moravek) in RPMI was added to 300,000 cells in fresh 0.75 mM glucose medium. The import was stopped after 30, 60 and 120 min by the addition of cold HBSS (Hank's balanced salt solution) containing the glucose transporter inhibitor cytochalasin B. The cells were next washed once with ice-cold HBSS and lysed in 400 ml RIPA (radio-immunoprecipitation assay) buffer with 1% SDS. Radioactive counts were determined by a scintillation counter and scintillation reads were normalized to the total protein concentration of each sample.
Metabolite profiling. For metabolite-concentration measurements, 10-million Jurkat cells were cultured in Nutrostats for 2 weeks before metabolite extraction. Cells were rapidly washed three times with cold PBS, and metabolites were extracted by the addition of 80% ice-cold methanol. Endogenous metabolite profiles were obtained using liquid chromatography-mass spectrometry (LC-MS) as described previously 26 . Metabolite levels (n 5 3 biological replicates) were normalized to cell number. Lactate and NAD(H) measurements. Lactate was measured as previously described 25 using the same medium that was used for glucose consumption measurements (above). NAD(H) was measured using the Fluoro NAD kit (Cell Technology FLNADH 100-2) in accordance with the manufacturer's protocol. Bioinformatic identification of cell lines with impaired glucose utilization. Gene expression data for all glycolytic genes and glucose transporters were compared between glucose-utilization-deficient cell lines (KMS-26 and NCI-H929) and all of the other cell lines, and those genes whose expression was significantly lower in the glucose-utilization-deficient lines were selected (SLC2A1, HK1, GAPDH, ENO1, GPI, TPI1 and PKM). SLC2A3 was also included as its expression was found to be significantly altered using qPCR (Fig. 3d ). Log 2 -transformed expression data for these eight genes was extracted for all 967 cell lines from the Cancer Cell Line Encyclopedia. For each cell line, we computed the difference between the expression level of each gene and the median expression level in all cell lines. For each gene, the cell lines were ranked in order of gene expression from lowest to highest, and these ranks were summed across all eight genes. ( Supplementary Table 4 ). Those cell lines included KMS-26 and NCI-H929, and from the other 30 cell lines with the lowest expression level of these genes, readily available lines were chosen. Identification of cell lines with mutations in mtDNA-encoded complex I subunits. Hybrid capture genome resequencing data of 912 cell lines from the Broad Institute Cancer Cell Line Encyclopedia (data kindly provided by L. Garraway) were mined for spurious mtDNA reads, which were aligned to the Revised Cambridge Reference Sequence. Sufficient data were obtained to reach an average of 53 coverage in 504 cell lines. Cell lines with frameshifting insertions or deletions in complex I subunits were identified from the data, and the presence of the predicted mutations confirmed by Sanger sequencing using the primers listed below in PCR followed by sequencing reactions. The degree of heteroplasmy was estimated based upon the ratio of the area under the curves of the wild-type allele to the mutant allele from Sanger sequence traces. Common variants were identified and filtered out by comparison to a database of such variants (MITOMAP: http://www.mitomap.org) and by the presence of these variants in .1% of the other cell lines in the CCLE set.
Primers for sequencing of mtDNA-encoded complex I genes: ND1, MT-ND1 forward, GGTTTGTTAAGATGGCAGAGCCC, MT-ND1 reverse, GATGGGTT CGATTCTCATAGTCCTAG; ND2, MT-ND2 forward, TAAGGTCAGCTAAAT AAGCTATCGGGC, MT-ND2 reverse, CTTAGCTGTTACAGAAATTAAGTA TTGCAAC; ND3, ND4L and 59 end of ND4, MT-ND3 and MT-ND4 forward, TTGATGAGGGTCTTACTCTTTTAGTATAAAT; MT-ND3 and MT-ND4 reverse, GATAAGTGGCGTTGGCTTGCCAT; 39 end of ND4, MT-ND4 forward, CCTTT TCCTCCGACCCCCTAACA; MT-ND4 reverse, TAGCAGTTCTTGTGAGCTT TCTCGGT; 59 end of ND5, MT-ND5 forward, AACATGGCTTTCTCAACTTTTA AAGGATAAC; MT-ND5 reverse, CGTTTGTGTATGATATGTTTGCGGTTTC; ND6 and 39 end of ND5, MT-ND5 and MT-ND6 forward, ACTTCAACCTCCCT CACCATTGG; MT-ND5 and MT-ND6 reverse, TCATTGGTGTTCTTGTAGTT GAAATACAAC. Cell counting. For cell proliferation assays, cell counting was carried out by plating cells in triplicate in 24-well plates at 5,000 to 20,000 cells per well in 2 ml RPMI base media under the conditions described in each experiment (that is, varying glucose concentration or phenformin treatment). After 4 days, the entire contents of the well were resuspended and counted (suspension cells) or trypsinized, resuspended and counted (adherent cells) using a Beckman Z2 Coulter Counter with a size selection setting of 8 to 30 mm. The increase in cell number compared to the initially plated sample was calculated and all values were normalized to their control in 10 mM glucose unless otherwise indicated. ATP-based measurements. ATP-based measurements for cell-proliferation assays were carried out by plating cells in replicates of five in 96-well plates at 500 to 1,000 cells per well in 200 ml RPMI base media under the conditions described in each experiment, and a separate group of five wells was also plated for each cell line with no treatment for an initial time point. After 5 h (untreated cells for initial time point) or after 3 days (with varying treatment conditions), 40 ml of Cell Titer Glo reagent (Promega) was added to each well, mixed briefly, and the luminescence read on a Luminometer (Molecular Devices). For wells with treatments causing an increase in luminescence, the fold change in luminescence relative to the initial luminescence was computed and this fold change for each condition was normalized to untreated wells (no effect 5 1). For wells with treatments causing a decrease in luminescence, the fold decrease in luminescence relative to the initial luminescence was computed (no viable cells present 5 21).
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qPCR. RNA was isolated using the RNeasy Kit (Qiagen) according to the manufacturer's protocol. RNA was spectrophotometrically quantified and equal amounts were used for cDNA synthesis with the Superscript II RT Kit (Invitrogen). To isolate genomic and mitochondrial DNA we used the Blood and Tissue Kit (Qiagen). qPCR analysis of gene expression or copy number was performed on an ABI Real Time PCR System (Applied Biosystems) with the SYBR green Mastermix (Applied Biosystems).
All primers were designed using the Primer3 software and aligned to the human reference genomes using blast to verify their specificity. The primers used for GLUT3 and GLUT1 are as follows GLUT1 forward and reverse, TCGTCGGCAT CCTCATCGCC and CCGGTTCTCCTCGTTGCGGT; GLUT3 forward and reverse, TTGCTCTTCCCCTCCGCTGC and ACCGTGTGCCTGCCCTTCAA. Results were normalized to RPL0 levels. Oxygen consumption. Oxygen consumption of intact or permeabilized cells was measured using an XF24 Extracellular Flux Analyzer (Seahorse Bioscience). For suspension cells, seahorse plates were coated with Cell TAK (BD, 0.02 mg ml 21 in 0.1 mM NaHO 3 ) for 20 min to increase adherence of suspension cells. Then 250,000 cells were attached to the plate by centrifugation at 1,000g, without brakes for 5 min. For adherent cells, 40,000 to 80,000 cells were plated the night before the experiments. RPMI 8226 (US biological no. 9011) was used as the assay media for all experiments with the indicated glucose concentrations in the presence of 2 mM glutamine without serum. For spare respiratory capacity measurements, increasing FCCP concentrations (0.1, 0.5 and 2 mM) were used in order to assess maximum OCR of each cell line. For basal oxygen consumption measurements, cell number or protein concentration was used for normalization.
Permeabilized cell measurements were performed as described previously 27 . In brief, cells were resuspended and plated (300,000 cells in 500 ml per well) in MAS-1 buffer (70 mM Sucrose, 220 mM Mannitol, 10 mM KH 2 PO 4 , 5 mM MgCl 2 , 2 mM HEPES, 1 mM EGTA, 0.2% fatty-acid-free BSA, pH 7.2). Saponin (50 mg ml 21 ), methyl pyruvate and malate (10 mM and 5 mM, respectively) were used for functional assessment of complex I, succinate (5 mM), rotenone (0.5 mM) and antimycin (1 mM) for functional assessment of complex II and III, TMPD and ascorbate (10 mM and 50 mM, respectively) for functional assessment of complex IV. 4 mM ADP was added to permeabilized cells to activate respiration in the mitochondria. We used the complex V inhibitor oligomycin (0.5 mM) to measure oxygen consumption in the absence of oxidative phosphorylation. All compounds were diluted in the assay buffer and injected into the wells sequentially as indicated for each experiment. Mouse xenografts. Xenografts were initiated with 2-to 5-million cells per injection site implanted subcutaneously into the right and left flanks of 5-to 8-week-old male NOD.CB17 Scid/J mice (Jackson Laboratories). Once tumours were palpable in all animals (.50 mm 3 volume by caliper measurements), mice were assigned randomly into biguanide treated or untreated groups and caliper measurements were taken every 3 to 4 days until tumour burden approached the limits set by institutional guidelines. Tumour volume was assessed according to the formula: 0.5 3 W 3 W 3 L or 1.33 3 W/2 3 L/2 3 D/2 for large tumours (W, width; L, length; D, depth). Phenformin was delivered in drinking water as described previously 15 at 1.7 mg ml 21 concentration with 5 mg ml 21 sucralose (Splenda), and metformin was delivered by daily intraperitoneal injection (300 mg kg 21 ). All experiments involving mice were carried out with approval from the Committee for Animal Care at MIT and under supervision of the Department of Comparative Medicine at MIT.
Mitochondrial DNA copy number and mass. For relative mitochondrial mass measurements, 2 3 10 5 cells were incubated directly with 50 nM Mitotracker Green FM (Invitrogen M7514) in RPMI for 40 min at 37 uC. Cells were then centrifuged at 1,000g for 5 min at 4 uC and the overlying media removed. Cells were kept on ice, washed once with ice-cold PBS, and resuspended in ice-cold PBS with 7-AAD (Invitrogen A1310) for FACS (fluorescence-activated cell sorting) analysis of live cells. The mean Mitotracker Green fluorescence intensity was used as a measure of relative mitochondrial mass.
For copy number, total DNA was isolated using the QIAamp DNA Minikit and qPCR was used to estimate relative differences in mtDNA copy number between different cell lines. Alu repeat elements were used as controls. Primers used are, ND1 forward and reverse, CCCTAAAACCCGCCACATCT and GAGCGATGG TGAGAGCTAAGGT; ND2 forward and reverse, TGTTGGTTATACCCTTCC CGTACTA and CCTGCAAAGATGGTAGAGTAGATGA; Alu forward and reverse, CTTGCAGTGAGCCGAGATT and GAGACGGAGTCTCGCTCTGTC. Selection of cells in phenformin. Cal-62 cells were selected at a concentration of phenformin that permitted half-maximal growth compared to the unselected line (approximately 5 mM for 2 weeks, 10 mM for 1.5 weeks, 15 mM for 1.5 weeks, and 20 mM for 1 week). Cells were split 1:10 when nearing confluence. After selection, cells were removed from phenformin for at least 3 days before starting proliferation assays. The ratio of wild-type to mutant mtDNA was calculated by summing the 11 Sanger sequencing peak height measurements per nucleotide position for both the wild-type and mutant allele allowing for the percentage of mutant mtDNA alleles to be calculated. These values were averaged over three nucleotide positions for which the base in the wild type and mutant sequence differs. Cell competition assay for KMS-26 cells with control and GLUT3 vector. KMS-26 cells with vector control and GLUT3 overexpression were mixed in equal amounts and an initial mixed sample was collected. Mixed cells were then cultured in different glucose concentrations in vitro and additionally injected subcutaneously to NOD-SCID mice. After 2.5 weeks, genomic DNA was isolated from initial sample, cells cultured in different glucose concentrations in vitro, and tumours grown in mice. Using a 59 common primer targeting the vector (AGTAGACGG CATCGCAGCTTGGATA) and 39 primers targeting the vector (GGCGGAATT TACGTAGCGGCC) or GLUT3 (GAGCCGATTGTAGCAACTGTGATGG), the abundance of the integrated viruses were determined by qPCR and the relative abundance of KMS-26 vector and KMS-26 GLUT3 cells inferred.
Statistics and animal-model statements. All experiments reported in Figs 1-4 were repeated at least three times in the laboratory, except Fig. 4f , g, which was performed once. t-tests were heteroscedastic to allow for unequal variance and distributions assumed to follow a Student's t distribution, and these assumptions are not contradicted by the data. No samples or animals were excluded from analysis, and sample size estimates were not used. Animals were randomly assigned into a treatment group with the constraint that the starting tumour burden in the treatment and control groups were similar. Studies were not conducted blind. a, Genes scoring as preferentially required for growth in 10 mM glucose compared to 0.75 mM glucose (top). shRNAs scores (given in per cent) and pathway classifications are indicated. Immunoblot analyses depict suppression of PKM by shRNAs (PKM1, PKM2) compared to control (RFP). Proliferation of cells in 0.75 mM (blue) relative to 10 mM glucose (black) harbouring shRNAs targeting PKM or control is also shown (PKM1). *P , 0.05 relative to RFP 0.75 mM glucose. b, Nuclear-encoded core complex I genes are shown in the grey box, with those that scored as differentially required under 0.75 mM glucose in red. The dot plot reports the degree of differential requirement for growth in 0.75 mM glucose (as the log 2 difference in shRNA abundance in 0.75 mM glucose versus 10 mM glucose) of individual shRNAs targeting non-core complex I genes, core complex I genes, or non-targeting controls. Red bar, population median. c, Top, mRNA levels of the non-scoring OXPHOS genes (black) and the scoring OXPHOS gene (blue) indicated upon suppression, with the shRNAs indicated as measured by qPCR, relative to a non-targeting shRNA (RFP). Bottom, cell number from 7-day proliferation assay of cells in 0.75 mM glucose relative to 10 mM glucose (not shown) harbouring the indicated shRNAs. shRFP control normalized to 1. Error bars are s.e.m., n 5 3. Replicates are biological, means reported. *P , 0.05 by two-sided student's t-test.

